Few factors influence a surgical device market more profoundly than reimbursement policy — and the MIS Sacroiliac Joint Fusion Market has experienced exactly that dynamic over the past decade. After years of inconsistent payer coverage decisions that constrained procedure growth, a landmark CMS policy change in 2025 has materially improved the commercial outlook for the market projected to reach USD 1.50 billion by 2035.

The Coverage Uncertainty Problem

MIS sacroiliac joint fusion emerged as a commercially available procedure category in the early 2010s, with SI-BONE's iFuse system pioneering the market. Despite accumulating clinical evidence supporting durable pain relief and functional improvement, the procedure faced persistent reimbursement challenges — primarily because large private payers and some Medicare Administrative Contractors (MACs) classified it as experimental or investigational pending additional evidence.

This coverage inconsistency created a fragmented market: patients with commercial insurance in certain regions or with certain plans could access the procedure; others with comparable pathology faced denials. The inconsistency also deterred some surgeons from investing in training and case volume development, knowing that reimbursement uncertainty could undermine practice economics.

CMS LCD L39810: The 2025 Turning Point

On April 17, 2025, CMS implemented Local Coverage Determination L39810 for minimally invasive sacroiliac joint arthrodesis — establishing standardized Medicare coverage criteria for MIS SIJ fusion procedures. This determination creates:

• Defined coverage criteria — Clear diagnostic requirements (imaging evidence, failed conservative treatment, positive diagnostic injection response) that both providers and payers can consistently apply
• Procedural code clarity — Established CPT code utilization guidance reducing billing and documentation ambiguity
• Precedent for private payer alignment — CMS coverage decisions typically catalyze commercial payer policy revisions, expanding coverage to a broader insured population over 12–24 months

The LCD L39810 implementation is expected to be the most commercially significant single event in the MIS SIJ fusion market since the original iFuse FDA clearance — directly expanding the addressable patient population by reducing coverage denials for Medicare beneficiaries and signaling legitimacy to commercial payers.

The Competitive Landscape Post-Coverage Expansion

The reimbursement improvement arrives in a market that has become significantly more competitive. SI-BONE pioneered MIS SIJ fusion and retains strong market position, but has been joined by multiple well-resourced competitors:

• Medtronic — Reline SI and other posterior approach systems leveraging its spine surgery commercial infrastructure
• Globus Medical — Integrated spine portfolio including MIS SIJ systems
• Enovis (formerly DJO/Colfax) — Posterior approach platform with strong orthopedic commercial relationships
• Orthofix — Expanding SIJ fusion product line
• CoreLink — March 2025 FDA clearance for Siber Ti system

This competitive density will accelerate procedure volume growth (through expanded commercial reach and surgeon outreach) while compressing device ASPs — a classic medical device market maturation dynamic.

Telehealth Integration: Pre- and Post-Operative Care Evolution

An emerging commercial opportunity in MIS SIJ fusion involves telehealth-enabled pre- and post-operative care pathways. Digital health platforms supporting remote patient-reported outcome collection, physical therapy coordination, and post-surgical monitoring are being developed in partnership with SIJ fusion device companies. This integration addresses a care continuum gap and creates value-added service relationships with hospital systems and ambulatory surgery centers.

FAQ

What is CMS LCD L39810? Local Coverage Determination L39810, implemented April 17, 2025, establishes Medicare coverage criteria for minimally invasive sacroiliac joint arthrodesis — creating consistent reimbursement access for eligible Medicare patients and providing commercial payer guidance.

How do private insurers cover MIS SIJ fusion after the CMS decision? Commercial payers typically align their coverage policies with CMS determinations over 12–24 months following a major LCD implementation. The 2025 CMS decision is expected to catalyze progressive private payer coverage improvements through 2026–2027.

What CPT codes are used for MIS SIJ fusion billing? The primary codes are CPT 27279 (arthrodesis, sacroiliac joint, percutaneous or minimally invasive, with image guidance) and CPT 27280 (open arthrodesis). CPT 27279 covers the vast majority of current MIS procedures.

#SacroiliacJointFusion #CMSCoverage #MedicalReimbursement #SpineSurgery #MISSacroiliacJointFusionMarket #HealthcarePolicy #SpineImplants #OrthopedicMarket #MedicalDevices